Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study by O'Brien, Susan, Prof, Jones, Jeffrey A, MD, Coutre, Steven E, Prof, Mato, Anthony R, MD, Hillmen, Peter, Prof, Tam, Constantine, MD, Österborg, Anders, Prof, Siddiqi, Tanya, MD, Thirman, Michael J, MD, Furman, Richard R, MD, Ilhan, Osman, Prof, Keating, Michael J, Prof, Call, Timothy G, MD, Brown, Jennifer R, MD, Stevens-Brogan, Michelle, MSc, Li, Yunfeng, PhD, Clow, Fong, ScD, James, Danelle F, MD, Chu, Alvina D, MD, Hallek, Michael, Prof, Stilgenbauer, Stephan, Prof

Get full text

A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moder... by Norito Katoh, MD, PhD, Yukihiro Ohya, MD, PhD, Hiroyuki Murota, MD, PhD, Masanori Ikeda, MD, PhD, Xiaofei Hu, PhD, Kimitoshi Ikeda, PhD, John Liu, MD, MS, Takuya Sasaki, Alvina D. Chu, MD, Henrique D. Teixeira, PhD, MBA, Hidehisa Saeki, MD, PhD

Get full text